IBM’s $12.5 Billion AI Pipeline Faces a Credibility Test as Mainframe Sales Crumble
Published on 07/24/2026 at 11:41 | Redaktion boerse-global.de
The arithmetic at IBM has turned uncomfortable. The company’s legacy mainframe business — long the profit engine that funds everything else — suffered a 42% revenue collapse in the second quarter of 2026, forcing management to slash its full-year growth forecast. Yet buried in the wreckage is a counter-narrative: $12.5 billion in generative AI bookings remain on the books, and CEO Arvind Krishna insists the damage is a matter of timing, not of lost market share.
The stock has been caught in the crossfire. After touching a 52-week low of €175.14 on July 23, shares have clawed back to around €183.00, but the year-to-date decline still stands at 30.07%. The 30-day annualized volatility has exploded to 84.02% — a reading that screams panic rather than measured repricing. The RSI(14) sits at 31.8, deep in oversold territory, suggesting the selling may have run its course mechanically even if the fundamental picture remains clouded.
The Timing Debate That Divides Wall Street
Krishna’s core argument is straightforward: customers pulled forward mainframe purchases in the first quarter to beat rising chip prices — the z17 system grew 51% in Q1 — and then went quiet in Q2 as budgets were reallocated toward AI infrastructure. The company now expects 75% of the delayed deals to close by year-end, and claims one-third already returned in the early weeks of the third quarter.
Wedbush analyst Dan Ives buys this thesis. He points to the $12.5 billion generative AI backlog as evidence that IBM’s strategic pivot remains intact, and dismisses the Q2 miss as a deal-closing hiccup rather than a demand shift. The software division offers some support: revenue rose 5% to €7.76 billion in the quarter, powered by 11% growth at Red Hat, and 80% of software sales are now subscription-based, providing a recurring revenue cushion.
Should investors sell immediately? Or is it worth buying IBM?
But the skepticism is loud and well-funded. Every major bank has slashed its price target, even if most have held their ratings steady. JPMorgan cut from $291 to $250 while keeping Overweight, calling the mainframe warning disappointing but noting the stock now trades at a discount to sum-of-the-parts. Argus went from $360 to $280, BofA from $330 to $280 — both maintaining Buy. Citi’s Fatima Boolani was the most aggressive, slashing from $375 to $255, though she too kept a Buy rating. Jefferies trimmed from $320 to $260.
The pattern is revealing: ratings hold, but targets drop sharply and uniformly. Oppenheimer broke ranks entirely, downgrading IBM from Outperform to Perform on the back of the weak guidance. The consensus now sits at €238.58, implying roughly 30% upside from current levels — a gap that looks tempting but reflects a bar that has been lowered considerably.
Structural Risk or Temporary Dislocation?
The bear case is not easily dismissed. Infrastructure revenue fell 7% to €3.84 billion in Q2, and IBM was forced to slash its software growth forecast from double-digit targets to a range of 6-8%. That suggests the AI boom is not merely cannibalizing mainframe hardware but also squeezing traditional software subscriptions as corporate budgets tilt decisively toward AI infrastructure.
JPMorgan’s Brian Essex, despite maintaining his Overweight rating, warned that the guidance revision reflects a real structural risk. He expects IBM to adopt a more conservative posture on future forecasts, with lower growth assumptions for 2026 across software, consulting, and the mainframe business. The company’s own free cash flow target — a projected year-over-year increase of roughly $1 billion — now carries added weight as a credibility marker.
Adding to the pressure, law firms are reportedly examining whether IBM’s disclosure around its deal pipeline was adequate before the July 14 profit warning. If the “delayed” deals fail to materialize in Q3, or if chip prices — up roughly 60% year-over-year — continue to squeeze customer budgets, the support near the 52-week low could be tested again.
The Third Quarter as Verdict
For now, the bulls have one powerful argument: virtually no major analyst has abandoned their positive rating entirely. Overweight and Buy calls still dominate, even at lower price targets. That combination — oversold technicals, reduced but still constructive targets, and a consensus pointing to recovery — typically marks a capitulation bottom rather than the start of a prolonged decline.
IBM at a turning point? This analysis reveals what investors need to know now.
The software business provides a second line of defense. With 80% of revenue on subscription models and Red Hat growing at 11%, the recurring base offers stability that pure-play hardware vendors lack. IBM’s internal AI assistant “Bob” is already used by over 80,000 employees, and the company has committed $10 billion to quantum computing, including the acquisition of HRL Laboratories. If either project achieves commercial breakthrough, the current 37.94% discount to the 52-week high could look like an overreaction.
But the clock is ticking. The next dividend payment of $1.69 per share arrives on September 10, 2026 — a routine event that will nonetheless be scrutinized for any signal of cash flow strain. More critically, the third-quarter results will either validate Krishna’s timing thesis or confirm that the mainframe business is suffering a structural erosion that no amount of AI bookings can mask. CFO Jim Kavanaugh has promised a “record year” for the mainframe division. That promise now hangs on whether the remaining two-thirds of delayed deals actually close.
The stock is statistically cheap and technically oversold. But the warning from the second quarter is real: the bar for a sustained recovery has been lowered, and the burden of proof now falls squarely on IBM’s ability to convert its pipeline into revenue. Until that happens, the gap between the $12.5 billion AI backlog and the 42% mainframe collapse will remain the defining tension in this story.
Ad
IBM Stock: New Analysis - 24 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
